ERK inhibition represses gefitinib resistance in non-small cell lung cancer cells

Mengfan Qi, Ye Tian, Wang Li, Dan Li, Tian Zhao, Yuxin Yang, Qiwen Li, Sujun Chen, Yan Yang, Zhixiong Zhang, Liang Tang, Zhonghua Liu, Bo Su, Fei Li, Yonghong Feng, Ke Fei, Peng Zhang, Fan Zhang, Lei Zhang

Research output: Contribution to journalArticle

Abstract

Gefitinib, an EGFR tyrosine kinase inhibitor, is used to treat non-small cell lung cancer (NSCLC) patients with activating EGFR mutations. However, the resistance to gefitinib eventually emerges in most of the patients. To understand its mechanism, we generated two acquired gefitinib-resistant NSCLC cell lines. The resistant cells have slower growth rates, but are more resistant to apoptosis in the presence of gefitinib, compared with their sensitive counterparts. In addition, our genome-wide transcriptome analysis reveals unexpected pathways, particularly autophagy, are dysregulated in the gefitinib-resistant cells. Autophagy is significantly enhanced in resistant cells. Importantly, inhibition of autophagy reduces gefitinib resistance. Furthermore, the phosphorylation of ERK, the extracellular signal-regulated kinase, is activated in resistant cells. Inhibition of ERK phosphorylation abrogates gefitinib resistance by suppressing autophagy both in vitro and in vivo. These findings establish a link between ERK and autophagy in gefitinib resistance, and suggest that the ERK signaling may serve as the potentially therapeutic target for treating gefitinib resistance in NSCLC patients.

Original languageEnglish (US)
Pages (from-to)12020-12034
Number of pages15
JournalOncotarget
Volume9
Issue number15
DOIs
StatePublished - Jan 1 2018

Fingerprint

Non-Small Cell Lung Carcinoma
Autophagy
Phosphorylation
gefitinib
Extracellular Signal-Regulated MAP Kinases
Gene Expression Profiling
Protein-Tyrosine Kinases
Genome
Apoptosis
Cell Line
Mutation
Growth

Keywords

  • Autophagy
  • ERK signaling
  • Gefitinib resistance
  • Non-small cell lung cancer

ASJC Scopus subject areas

  • Oncology

Cite this

Qi, M., Tian, Y., Li, W., Li, D., Zhao, T., Yang, Y., ... Zhang, L. (2018). ERK inhibition represses gefitinib resistance in non-small cell lung cancer cells. Oncotarget, 9(15), 12020-12034. https://doi.org/10.18632/oncotarget.24147

ERK inhibition represses gefitinib resistance in non-small cell lung cancer cells. / Qi, Mengfan; Tian, Ye; Li, Wang; Li, Dan; Zhao, Tian; Yang, Yuxin; Li, Qiwen; Chen, Sujun; Yang, Yan; Zhang, Zhixiong; Tang, Liang; Liu, Zhonghua; Su, Bo; Li, Fei; Feng, Yonghong; Fei, Ke; Zhang, Peng; Zhang, Fan; Zhang, Lei.

In: Oncotarget, Vol. 9, No. 15, 01.01.2018, p. 12020-12034.

Research output: Contribution to journalArticle

Qi, M, Tian, Y, Li, W, Li, D, Zhao, T, Yang, Y, Li, Q, Chen, S, Yang, Y, Zhang, Z, Tang, L, Liu, Z, Su, B, Li, F, Feng, Y, Fei, K, Zhang, P, Zhang, F & Zhang, L 2018, 'ERK inhibition represses gefitinib resistance in non-small cell lung cancer cells', Oncotarget, vol. 9, no. 15, pp. 12020-12034. https://doi.org/10.18632/oncotarget.24147
Qi, Mengfan ; Tian, Ye ; Li, Wang ; Li, Dan ; Zhao, Tian ; Yang, Yuxin ; Li, Qiwen ; Chen, Sujun ; Yang, Yan ; Zhang, Zhixiong ; Tang, Liang ; Liu, Zhonghua ; Su, Bo ; Li, Fei ; Feng, Yonghong ; Fei, Ke ; Zhang, Peng ; Zhang, Fan ; Zhang, Lei. / ERK inhibition represses gefitinib resistance in non-small cell lung cancer cells. In: Oncotarget. 2018 ; Vol. 9, No. 15. pp. 12020-12034.
@article{deadbb3ec1be44568736a9b212116056,
title = "ERK inhibition represses gefitinib resistance in non-small cell lung cancer cells",
abstract = "Gefitinib, an EGFR tyrosine kinase inhibitor, is used to treat non-small cell lung cancer (NSCLC) patients with activating EGFR mutations. However, the resistance to gefitinib eventually emerges in most of the patients. To understand its mechanism, we generated two acquired gefitinib-resistant NSCLC cell lines. The resistant cells have slower growth rates, but are more resistant to apoptosis in the presence of gefitinib, compared with their sensitive counterparts. In addition, our genome-wide transcriptome analysis reveals unexpected pathways, particularly autophagy, are dysregulated in the gefitinib-resistant cells. Autophagy is significantly enhanced in resistant cells. Importantly, inhibition of autophagy reduces gefitinib resistance. Furthermore, the phosphorylation of ERK, the extracellular signal-regulated kinase, is activated in resistant cells. Inhibition of ERK phosphorylation abrogates gefitinib resistance by suppressing autophagy both in vitro and in vivo. These findings establish a link between ERK and autophagy in gefitinib resistance, and suggest that the ERK signaling may serve as the potentially therapeutic target for treating gefitinib resistance in NSCLC patients.",
keywords = "Autophagy, ERK signaling, Gefitinib resistance, Non-small cell lung cancer",
author = "Mengfan Qi and Ye Tian and Wang Li and Dan Li and Tian Zhao and Yuxin Yang and Qiwen Li and Sujun Chen and Yan Yang and Zhixiong Zhang and Liang Tang and Zhonghua Liu and Bo Su and Fei Li and Yonghong Feng and Ke Fei and Peng Zhang and Fan Zhang and Lei Zhang",
year = "2018",
month = "1",
day = "1",
doi = "10.18632/oncotarget.24147",
language = "English (US)",
volume = "9",
pages = "12020--12034",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "15",

}

TY - JOUR

T1 - ERK inhibition represses gefitinib resistance in non-small cell lung cancer cells

AU - Qi, Mengfan

AU - Tian, Ye

AU - Li, Wang

AU - Li, Dan

AU - Zhao, Tian

AU - Yang, Yuxin

AU - Li, Qiwen

AU - Chen, Sujun

AU - Yang, Yan

AU - Zhang, Zhixiong

AU - Tang, Liang

AU - Liu, Zhonghua

AU - Su, Bo

AU - Li, Fei

AU - Feng, Yonghong

AU - Fei, Ke

AU - Zhang, Peng

AU - Zhang, Fan

AU - Zhang, Lei

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Gefitinib, an EGFR tyrosine kinase inhibitor, is used to treat non-small cell lung cancer (NSCLC) patients with activating EGFR mutations. However, the resistance to gefitinib eventually emerges in most of the patients. To understand its mechanism, we generated two acquired gefitinib-resistant NSCLC cell lines. The resistant cells have slower growth rates, but are more resistant to apoptosis in the presence of gefitinib, compared with their sensitive counterparts. In addition, our genome-wide transcriptome analysis reveals unexpected pathways, particularly autophagy, are dysregulated in the gefitinib-resistant cells. Autophagy is significantly enhanced in resistant cells. Importantly, inhibition of autophagy reduces gefitinib resistance. Furthermore, the phosphorylation of ERK, the extracellular signal-regulated kinase, is activated in resistant cells. Inhibition of ERK phosphorylation abrogates gefitinib resistance by suppressing autophagy both in vitro and in vivo. These findings establish a link between ERK and autophagy in gefitinib resistance, and suggest that the ERK signaling may serve as the potentially therapeutic target for treating gefitinib resistance in NSCLC patients.

AB - Gefitinib, an EGFR tyrosine kinase inhibitor, is used to treat non-small cell lung cancer (NSCLC) patients with activating EGFR mutations. However, the resistance to gefitinib eventually emerges in most of the patients. To understand its mechanism, we generated two acquired gefitinib-resistant NSCLC cell lines. The resistant cells have slower growth rates, but are more resistant to apoptosis in the presence of gefitinib, compared with their sensitive counterparts. In addition, our genome-wide transcriptome analysis reveals unexpected pathways, particularly autophagy, are dysregulated in the gefitinib-resistant cells. Autophagy is significantly enhanced in resistant cells. Importantly, inhibition of autophagy reduces gefitinib resistance. Furthermore, the phosphorylation of ERK, the extracellular signal-regulated kinase, is activated in resistant cells. Inhibition of ERK phosphorylation abrogates gefitinib resistance by suppressing autophagy both in vitro and in vivo. These findings establish a link between ERK and autophagy in gefitinib resistance, and suggest that the ERK signaling may serve as the potentially therapeutic target for treating gefitinib resistance in NSCLC patients.

KW - Autophagy

KW - ERK signaling

KW - Gefitinib resistance

KW - Non-small cell lung cancer

UR - http://www.scopus.com/inward/record.url?scp=85042431645&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042431645&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.24147

DO - 10.18632/oncotarget.24147

M3 - Article

AN - SCOPUS:85042431645

VL - 9

SP - 12020

EP - 12034

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 15

ER -